Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer

Overview of attention for article published in The Journal of Urology, September 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

policy: 1 policy source
twitter: 4 X users
patent: 8 patents

facebook: 1 Facebook page
guideline: 2 clinical guideline sources

Readers on

mendeley: 57 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

Prolaris gene expression assay for assessing long-term risk of prostate cancer progression

Cited by National Institute for Health and Care Excellence (NICE) on 24 May 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

Prolaris gene expression assay for assessing long-term risk of prostate cancer progression

Cited by National Institute for Health and Care Excellence (NICE) on 01 May 2016

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.